Companies Backed by Northpond Ventures
5 companies in Northpond Ventures's investment portfolio.
Back to Northpond Ventures profileInvestment Thesis
“Investing in life sciences companies that harness breakthrough scientific discoveries to develop transformational medicines and medical technologies.”
Portfolio Companies (3)
10x Genomics
10x Genomics makes instruments, consumables and software for single-cell and spatial biology research. It went public on Nasdaq (TXG) in September 2019 and reported $642.8 million of revenue for 2025.
Guardant Health
Guardant Health develops blood-based liquid biopsy tests for cancer, led by Guardant360. It went public on Nasdaq as GH in October 2018 after raising about $550 million privately.
Veracyte
Veracyte is a South San Francisco genomic diagnostics company whose tests cover thyroid, prostate, breast and lung cancer. It went public on Nasdaq (VCYT) in October 2013 and reported $517M in revenue for 2025.
Other Investments (2)
Portfolio Analysis
Northpond Ventures has built a portfolio of 5 companies across 1 sector, including Biotech. Of these investments, 3 have achieved successful exits through acquisitions or IPOs, demonstrating the firm's track record of backing companies to meaningful outcomes.
The portfolio reflects investments across the IPO stage, showing Northpond Ventures's approach to supporting companies at a focused stage of development.
Frequently Asked Questions
How many companies has Northpond Ventures invested in?
Northpond Ventures has invested in 5+ companies across 1 different sectors. Of these, 3 have achieved successful exits through acquisitions or IPOs.
What sectors does Northpond Ventures invest in?
Northpond Ventures's portfolio spans Biotech. This diversification reflects the firm's broad investment thesis and sector expertise.
What stages does Northpond Ventures invest at?
Northpond Ventures invests across the IPO stage. Their portfolio includes companies at various points in their growth journey.
How many exits has Northpond Ventures had?
Northpond Ventures has had 3 portfolio companies achieve exits through acquisitions or IPOs. This track record of exits demonstrates the firm's ability to identify and support companies through successful outcomes.